title: [Chronic myelogenous leukemia].
abstract: In the therapy of chronic myelogenous leukemia (CML), interferon (IFN) brought about a big progress resulting in the good hematologic as well as cytogenetic response and prolongation of survival. Recently, imatinib, the BCR/ABL antagonist, took over the first choice drug of the treatment CML. However, IFN still has the possibility to contribute the improvement of the therapy efficacy of CML.
authors.affiliation: Center for Preventive Medicine, NTT Kanto Medical Center.
authors.forename: Akio
authors.initials: A
authors.lastname: Urabe
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D003561:Cytarabine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D016313:Genes, abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy*; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D003561:Cytarabine; D000068877:Imatinib Mesylate